OTC sales fell a catastrophic 53% in 4th Quarter !
The problem at JNJ is they have clearly taken their eye off the ball and even after repeated recalls of products for quality control problems they still have not stepped up efforts internally to an adequate degree. It calls into question the competence and capability of management. I own 900 shares and feel that it has been dead money for two years while the S&P has done quite well. I also think these problems have impacted the stock price negatively and reduces shareholder's wealth. Not exactly why one invests. I recommend a vote against all incumbent directors and all management supported proposals in the proxy.